Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials

B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
被引用次数：26 相关文章

Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.

B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer (Amsterdam …, 2018 - europepmc.org
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials

B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - lungcancerjournal.info
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials

B Zhao, W Zhang, D Yu, J Xu… - Lung cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …